论文部分内容阅读
链脲佐菌素(STZ)制备糖尿病大鼠模型,分为正常对照组、糖尿病非治疗组、糖尿病药物治疗组,观察血糖、血肌酐、尿微量白蛋白排泄率、肾组织光镜下PA S染色、免疫组织化学及电镜下的改变。结果:与对照组相比,糖尿病组及治疗组尿微量白蛋白排泄率、肾组织TGF-1β、PPAR-γ表达增加(P<0.01),病理改变明显。而治疗组尿微量白蛋白排泄率、肾组织TGF-1β、PPAR-γ表达低于糖尿病组(P<0.05),病理改变减轻。结论:罗格列酮可活化PPAR-γ,下调TGF-1β,减少糖尿病大鼠尿蛋白,对糖尿病肾病起保护作用。
Streptozotocin (STZ) was used to prepare diabetic rat model and divided into normal control group, untreated diabetic group and diabetic drug-treated group. Blood glucose, serum creatinine and urinary albumin excretion rate were observed. Staining, immunohistochemical and electron microscopy changes. Results: Compared with the control group, the urinary albumin excretion rate and the expression of TGF-β, PPAR-γ in diabetic group and treatment group were increased (P <0.01), and the pathological changes were obvious. The urinary albumin excretion rate in the treatment group was lower than that in the diabetic group (P <0.05), and the pathological changes were alleviated. CONCLUSION: Rosiglitazone can activate PPAR-γ, down-regulate TGF-1β, reduce urinary protein in diabetic rats and protect diabetic nephropathy.